Kodiak Sciences (KOD) Expected to Announce Quarterly Earnings on Wednesday

Kodiak Sciences (NASDAQ:KOD) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($1.01) per share for the quarter.

Kodiak Sciences (NASDAQ:KOD) last announced its earnings results on Wednesday, May 14th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.20). On average, analysts expect Kodiak Sciences to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kodiak Sciences Stock Up 1.6%

Shares of KOD opened at $8.03 on Tuesday. The business’s 50 day moving average is $5.14 and its two-hundred day moving average is $4.34. Kodiak Sciences has a 52-week low of $1.92 and a 52-week high of $11.60. The firm has a market cap of $423.66 million, a price-to-earnings ratio of -2.21 and a beta of 2.41.

Hedge Funds Weigh In On Kodiak Sciences

A number of institutional investors have recently made changes to their positions in the business. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Kodiak Sciences during the 1st quarter valued at approximately $94,000. Jane Street Group LLC raised its position in shares of Kodiak Sciences by 441.3% during the 1st quarter. Jane Street Group LLC now owns 64,649 shares of the company’s stock valued at $181,000 after acquiring an additional 52,705 shares in the last quarter. Finally, AQR Capital Management LLC acquired a new stake in shares of Kodiak Sciences during the 1st quarter valued at approximately $188,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.